Rare diseases
Investigational molecules
Locations
EVO756 potassium is a chemically synthesised substance (a small molecule) developed by Evommune, Inc. It is an investigational medicine, which means it has not yet received a marketing authorisation and is not available as a licensed treatment.[1] The substance is given by mouth as a tablet.[1] In the registry records, it appears under the product name EVO756 Potassium and is classified within the therapeutic area of skin and connective tissue diseases.[1]
The available registry data do not describe the molecular target or mechanism of action of EVO756 potassium. The completed trial was designed as a dose-ranging study to evaluate efficacy and safety in chronic spontaneous urticaria, but the precise way the substance acts in the body is not stated in the trial record.[1]
EVO756 potassium is formulated as a tablet for oral use.[1] The trial record lists several oral dose levels of EVO756 potassium, each described as 1 mg in the intervention entries, alongside a placebo arm.[1]
One completed Phase 2 trial of EVO756 potassium is registered in the EU Clinical Trials Information System.[1] The study enrolled 164 adults with moderate to severe chronic spontaneous urticaria and compared multiple oral dose levels of EVO756 potassium against placebo.[1] The primary outcome was the mean change from baseline in UAS7 at week 12. UAS7 stands for Urticaria Activity Score over 7 days, a patient-reported measure that combines daily itch severity and hive counts into a weekly score; a larger drop in UAS7 indicates greater improvement.[1] The trial is listed as completed, but the registry record does not include the study results.[1]
No side effect data for EVO756 potassium are provided in the registry record or in any supplementary source, so a side effect profile cannot be described here.
Each condition opens its own overview and trial list
Recruiting trials first
Tell us about your condition – we search every trial in Europe and connect you with the right site.
